Thank you for visiting the website of the New York State Neurological Society (NYSNS)! You can use the top menu to discover who we are and how to join as well as find resources for neurologists and the most recent updates on our December 14, 2019 Annual Winter Meeting.  Feel free to contact us if you have any questions or want more information!

Migraine Regional CME  In June

Rethinking Migraine Treatment: 
New Therapies Impacting Patient Care

by Forefront Collaborative

CME!  No Charge!
Light Supper!
Wednesday, June 26, 2019
5:30 p.m. – 7:30 p.m.
Stewart Hotel
371 7th Avenue at 31st Street
New York, NY 10001
Matthew Robbins, MD, FAAN, FAHS
Lawrence Newman, MD



Save the Date:  12/14/19!

The NYSNS will hold its Annual Winter Meeting on Saturday, December 14, 2019, in New York City at the Stewart Hotel.  Watch for more information, but hold that date.  There are some great speakers and programs to come!

Welcome Our New Board Members


Goel Dzh1YI5X0AEG8Kv


The New York State Neurological Society (NYSNS) welcomes new Board members and officers for 2019.  Doctor Gil I. Wolfe took the gavel as president at the conclusion of the January 5, 2019 meeting.  Moving into other officer positions were Mill Etienne, MD as Vice President/President-Elect, Allan Perel, MD as Treasurer, and Matthew Robbins, MD as Secretary.  Two new Board members have come on as well.  As of January 13, the Society welcomes Sweta Goel, MD and Melissa Rayhill, MD.  (To see all our Board members and their brief bios, go to the Board of Directors tab at the top of the home page.)   We are glad to have Doctor Goel (left) and Doctor Rayhill (right) “aboard.”

NY Neurosociety Meeting

Member Perspective by Gil I. Wolfe, MD, FAAN, NYSNS President

The following is from the January 21, 2019, Capitol Hill Report, American Academy of Neurology (reprinted with permission) 

The New York State Neurological Society (NYSNS) held its annual Winter Meeting on January 5, 2019, in New York City. Attendance at this year’s educational meeting grew significantly from prior years to more than 150 attendees, including some 20 exhibitors, and offered 6.5 hours of CME credit. Topics included therapy updates in multiple sclerosis, epilepsy, headache and stroke. There were also presentations on medical cannabis, telemedicine, and improving quality of life in Parkinson’s disease. The meeting included two workshops offering hands-on experience in headache procedures and vagal nerve stimulation in epilepsy.

Each year, the NYSNS Winter Meeting features the Neurostakes competition between New York-based neurology residency training programs, a trivia contest in the vein of the TV game show Jeopardy. Six teams of mostly senior neurology residents competed this year, with SUNY Stony Brook coming out on top. Mill Etienne, MD, MPH, FAAN, treasurer of the society, served as MC of the competition. Annual Meeting Committee members included Andrew D. Goodman, MD, FAAN, outgoing president of the society, in addition to Charles Esenwa, MD; Mill Etienne, MD, MPH, FAAN; Matthew S. Robbins, MD, FAAN; and Nilay R. Shah, MD. Cheryl Malone, executive director of NYSNS, played a key role in the meeting’s success.

The NYSNS has plans for smaller, regional meetings during the year, with the next Winter Meeting tentatively planned for October 2019. Check the NYSNeurology.com website for future information.

State neurological societies across the country not only fill an educational role for health care providers but are often involved with advocacy efforts at the state level. For instance, the NYSNS has an Advocacy Committee chaired by Allan Perel, MD, FAAN that monitors issues important to neurologists making their rounds in Albany. Supporting the work of state neurological societies is one of the roles of the Government Relations Committee of the AAN.

Thanks to Our Leadership

Gavel is Passed to Doctor Gil Wolfe at at the Annual Winter Meeting

Below new president Gil Wolfe, MD; past president John Ferro, MD; and outgoing president Andrew Goodman, MD.  Doctor Wolfe helped us celebrate Doctors Ferro and Goodman at the Annual Winter Meeting on January 5, 2019.


thanks to our leadership

The  Annual Winter  Meeting =

A Great Success

What a great meeting!   We hope you were able to join us on January 5.  The Board of Directors of NYSNS is already thinking about the next event, so stay tuned.

Our thanks to our speakers:  Fiona Gupta, MD; Fred Lublin, MD; Matthew Robbins, MD; Robert Glover, MD; Mill Etienne, MD; Lazlo Mechtler, MD; Shazia Alam, DO; and Eric Anderson, MD, PhD.  We heard the latest on Parkinson’s, MS, Headache Therapy, Epilepsy, Medical Cannabis, Stroke, and Telemedicine.  The audience was engaged, and everyone enjoyed the program and networking.

It’s not an NYSNS Meeting without the Neurostakes Competition.  This year the Competition was sponsored by Sunovion Pharmaceuticals.  Our intrepid residents from programs at the University of Rochester, Mt. Sinai, SUNY Upstate, Stony Brook, Albany, and  Northwell Health Hofstra all faced off against quizmaster Mill Etienne, MD.   After a close competition, Stony Brook were this year’s champions.  Congratulations to the Stony Brook  Team:  Cara Harth, MD; Kamil Stefanowski, MD; Alexander C. Ou, MD; and Kathryn Cooper, MD. 

Thanks to all the teams pictured below.

neurostakes teams 2019 img_0064


Here’s the winning team from Stony Brook below.

winning team from stonybrook!



Thanks to our exhibitors and CME providers below for helping to make it all possible.


Gold                                                         Sunovion Pharmaceuticals





Catamount Medical Education*

*CME Provider 



Acadia Pharmaceutials

CLS Behring

Sanofi Genzyme

US WorldMeds



 Biotel Heart Caridonet/Lifewatch


NeuroNet GPO



Quest Diagnostics   


Strongbridge BioPharma

GE Health Care: DatSca

Adamas Pharmaceuticals 



Supernus Pharmaceuticals         


Vertical Pharmaceuticals 

Akcea Therapeutics

Ipsen Biopharmaceuticals


See you at the next meeting!

January 5, 2019 Annual Winter Meeting Agenda

Here’s the VERY Latest Program Details!

*Utilizing Advanced Science to Improve the Quality of Life in Patients with Parkinson’s Disease* with Fiona Gupta, MD,  The Mt. Sinai Hospital, Assistant Professor of Neurology

The above  portion of the agenda is a CME Category I Program provided by AcademicCME  *This activity is supported by an educational grant from Acorda*   AcademicCME is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. AcademicCME designates this live material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

*Immune Dysfunction in Multiple Sclerosis: CMS Modern Considerations in Treatment and Management*  with Fred D. Lublin, MD, Saunders Family Professor of Neurology, Director of the Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Icahn School of Medicine at Mount Sinai

The above portion of the agenda is provided by the Consortium of Multiple Sclerosis Centers (CMSC), International Organization of Multiple Sclerosis Nurses (IOMSN), and Catamount Medical Education and supported by educational grants from Biogen, EMD Serono, Genzyme, and Novartis Pharmaceuticals Corporation.

In support of improving patient care, this activity has been planned and implemented by the CMSC, IOMSN, and Catamount Medical Education. CMSC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. For CE information, including statements of credit, please visit  Catamount CME for Immune Dysfunction in MS. 

Headache Therapy Update with Matthew S. Robbins, MD, Neurology Residency Program Director, Weill Cornell Medicine and New York Presbyterian Hospital

New Treatments in Epilepsy with Robert Glover, MD,  Clinical Assistant Professor, Department of Neurology, University of Buffalo, Jacobs School of Medicine and Biomedical Sciences 

Headache Procedure Workshop / VNS Demos with Doctor Robbins and Joshua M. Cohen, MD, MPH,  Global Therapeutic Area Lead for Migraine & Headache, Teva Pharmaceuticals; and  Doctor Glover and Mill Etienne, MD, MPH, FAAN, Director of the Epilepsy and EEG Laboratory at Good Samaritan Regional Medical Center,   and Assistant Professor of Neurology at the New York Medical College.

An Overview and Update on Medical Cannabis  with Laszlo L. Mechtler, MD, Medical Director, Dent Neuorlogic Institute, Professor of Neuorology and Neuro-Oncology, State University of New York at Buffalo

Stroke Update with Shazia Alam, DO,  Director, Neurohospitalist & Stroke Services, NYU Winthrop Hospital

Telemedicine Update with Eric R. Anderson, MD, PhD,  Director of Telemedicine, Corticare.

The above  portion of the agenda is a CME Category I Program provided by MLMIC. 

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Medical Society of the State of New York (MSSNY) through the joint providership of MLMIC Insurance Company (MLMIC) and the New York State Neurological Society.  MLMIC is accredited by MSSNY to provide continuing medical education for physician.  MLMIC designates this live activity for a maximum of 4.0 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Check Out The Newest MLMIC Case Review

As previously discussed in the Spring 2017 1ssue of Dateline, MLMIC Insurance
Company is increasingly using summary judgment motions to successfully defend
medical professional liability lawsuits commenced against its policyholders, thus
precluding the need for a lengthy and expensive trial The following IS one such case.


MLMIC (NYSNS Endorsed) Earns A+ Rating According to AM Best

AM Best has assigned a Financial Strength Rating of A+ (Superior) and a Long-Term Issuer Credit Rating of “aa-” to MLMIC Insurance Company (MLMIC) (New York, NY). The outlook assigned to these Credit Ratings (ratings) is stable.

The ratings reflect MLMIC’s balance sheet strength, which AM Best categorizes as strongest, as well as its adequate operating performance, limited business profile and appropriate enterprise risk management. The ratings also benefit from the financial support provided by MLMIC’s direct parent company, National Indemnity Company, which is ultimately owned by Berkshire Hathaway Inc. [NYSE: BRK.A and BRK.B].

MLMIC’s risk-adjusted capitalization, as measured by Best’s Capital Adequacy Ratio (BCAR) is categorized as strongest and AM Best expects it to remain at a similar level in prospective years. The balance sheet strength assessment also considers the company’s track record of positive reserves development, as well as good financial flexibility provided by its publicly traded ultimate parent Berkshire Hathaway Inc.

MLMIC has historically generated an adequate level of operating results, supported by modest underwriting profits and moderate investment returns. Underwriting results have consistently benefited from reserve releases on prior accident years. Prospectively, AM Best does not expect any material change in the company’s profitability levels.

MLMIC’s insurance portfolio is concentrated in the medical malpractice line of business. The company underwrites risks only within New York state, which represents one of the nation’s most challenging market environments. However, management has been able to operate successfully through underwriting cycles while maintaining MLMIC’s leading market position within New York. In addition, risk management capabilities have proven appropriate for the risk profile of the company.

MLMIC is the only endorsed medical liability company of the New York State Neurological Society.  To learn more go to https://www.mlmic.com/  


CMS: New Quality Payment Program Resources Available and New Site Look

The Centers for Medicare & Medicaid Services (CMS) has recently revamped the look of the Quality Payment Program website and also posted new resources to help clinicians successfully participate in the first year of the Quality Payment Program.

CMS encourages clinicians to visit the website to review the following new resources:

  • MIPS Quick Start Guide: Outlines the steps MIPS clinicians need to take between now and March 2018 to prepare for and participate in MIPS, including checking participation status, choosing to participate as an individual or as part of a group, deciding how to submit data, and selecting measures and activities.
  • Medicare Shared Savings Program and Quality Payment Program Fact SheetExplains how the Shared Savings Program and the Quality Payment Program align reporting requirements for participating Accountable Care Organizations (ACOs) and MIPS clinicians, and how certain tracks in Shared Savings Program ACOs meet Advanced Alternative Payment Model (APM) criteria under the Quality Payment Program.
  • MIPS APM Fact Sheet: Provides an overview of a specific type of APM, called a MIPS APM, and the special APM scoring standard used for those in MIPS APMs.

Federal Legislative Updates

Senators Rubio and Sinema are leading a letter addressed to CMS Administrator Verma, asking CMS to reconsider its proposal to undermine the six protected classes in Medicare Part D.

The six protected classes policy gives beneficiaries access to all or substantially all medications within the six categories of drugs: antiretrovirals, immunosuppressants, antidepressants, antipsychotics, anticonvulsants, and oncology drugs. Under CMS’ proposal, Part D plans could create new barriers for patients by requiring beneficiaries get prior authorizations for these drugs or utilize step therapy.

Please CALL:

·  Leader Chuck Schumer: (202) 224-6542

·  Senator  Kirsten Gillibrand: (202) 224-4451

And SAY:

·  I understand there is a letter circulating with your colleagues asking CMS to reconsider its proposal to undermine the six protected classes in Medicare Part D

·  This proposal could create new barriers for patients by requiring beneficiaries get prior authorizations for lifesaving drugs or utilize step therapy.

·  Please sign-on to this letter today in support of patients in New York and around the country.

State Legislative Updates


June 19, 2019

The State Legislature is currently considering multiple bills that would drastically increase medical liability insurance premiums and decrease patients’ access to essential health care services.  Malpractice payouts in New York State continue to be far out of proportion to the rest of country, and WalletHub has again listed New York as the worst state in the country in which to be a doctor.  Send emails right now!  Go to  Write an Email NOW

June 14, 2019

The New York State Neurological Society is proud to have been part of the coalition that fought for immunizations and a stop to the measles epidemic in New York.   If you have a moment, thank Assemblymember Jeffrey Dinowitz (office number  (518) 455-5965) from the Bronx  and Senator Brad Hoylman (office number  (518)455-2451) from  Manhattan.  They continued a fight in the face of vocal and intimidating opposition.

Cuomo signs ban on nonmedical vaccine exemptions via

May 4, 2019

The Board of Directors of NYSNS has signed on with a number of other medical societies around the State of New York supporting  1) Assembly Bill 2371/Senate Bill 2994 which would clarify that the only permissible exception from New York’s vaccination requirements is for patient medical conditions that would place patients who are immunized at risk for adverse outcome; and 2)  Assembly Bill 3038/Senate Bill 2847 which would significantly reduce the exorbitant pre-authorization barriers experienced by patients and their physicians that get in the way of timely treatment and medication and would help to protect consumers’ access to their prescription drugs.

AAN  Updates


MSSNY  Updates

Workers’ Compensation News

The Medical Society of the State of New York reports that the New York State Department of Financial Services has decided to delay implementation of the recently updated Workers’ Compensation  Medical Fee Schedule until October 1, 2020 for the Auto No-Fault Program. 

Therefore, you will need to keep the Workers’ Compensation Fee Schedule that was effective on June 1, 2012 for billing claims for the treatment of persons injured as the result of auto accidents.

Public comment  can be sent to Camielle.Barclay@dfs.ny.gov   before April 22, 2019.


Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s